Crossmark

Genome Engineering for Osteoarthritis: From Designer Cells to Disease-Modifying Drugs

Crossref DOI link: https://doi.org/10.1007/s13770-018-0172-4

Published Online: 2019-01-05

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Choi, Yun-Rak https://orcid.org/0000-0001-5197-3716
Collins, Kelsey H.

Lee, Jin-Woo

Kang, Ho-Jung

Guilak, Farshid https://orcid.org/0000-0001-7380-0330
Funding

Funding for this research was provided by:

Foundation for the National Institutes of Health (AR48852)

Foundation for the National Institutes of Health (AG15768)

Foundation for the National Institutes of Health (AR48182)

Foundation for the National Institutes of Health (AG46927)

Foundation for the National Institutes of Health (OD10707)

Foundation for the National Institutes of Health (DK108742)

Foundation for the National Institutes of Health (EB018266)

Foundation for the National Institutes of Health (P30 AR057235)

Arthritis Foundation

Nancy Taylor Foundation for Chronic Diseases
License Information

Text and Data Mining valid from 2019-01-05
More Information

Article History

Received: 16 October 2018

Revised: 27 November 2018

Accepted: 1 December 2018

First Online: 5 January 2019

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: There are no animal experiments carried out for this article.